Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AstraZeneca

BioNTech SE

GlaxoSmithKline

Inovio Pharmaceuticals

Merck

Valneva SE

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Regeneron Pharmaceuticals

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT).

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx's AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. Financial terms of the partnership are not disclosed. “Today, only 5% of rare diseases have an approved t.

Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role in treatments in the next decades to come. The stock currently offers a 4% dividend yield, while trading below its moving average and with a mixed valuation picture vs key peers.

Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive

BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multiple national regulatory authorities (NRAs) around the globe. As industry leaders are set to leverage the Accumulus platform for upcoming projects, its ability to handle concurrent submissions across multiple jurisdictions is proving to be a game-changer.

The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, November 6, 2024. The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age.

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Sanofi Cancels Consumer Healthcare Business Spin-Off

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach positions Resalis to pot.

Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

Why Sanofi Stock Flew Higher on Friday

Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply Roy Papatheodorou - Executive Vice President, General Counsel Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Graham Parry - BofA Seamus Fernandez - Guggenheim Jo Walton - UBS Peter Welford - Jefferies Luisa Hector - Berenberg Thibault Boutherin - Morgan Stanley Simon Baker - Redburn Steve Scala - TD Cowen David Risinger - Leerink Richard Parkes - BNP Exane Rajesh Kumar - HSBC Eric Berrigaud - Stifel Florent Cespedes - Bernstein Thomas Kudsk Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.

Sanofi (SNY) Q3 2024 Earnings Call Transcript

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

The pharmaceutical company reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for blockbuster anti-inflammatory drug Dupixent.

Sanofi Earnings Boosted by Early Vaccine Sales

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.

Sanofi Q3 earnings beat market view, boosted by vaccine sales

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the US suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines Paris and Tarrytown, NY, October 24, 2024. Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background therapy with antihistamines will be presented in a late-breaking oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts.

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.

Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks for a deal that values the business at $17.4 billion, including debt.

Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale

France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the business to US private equity firm Clayton, Dubilier & Rice (CD&R), despite political opposition. Sanofi entered exclusive talks with CD&R to sell 50% of Opella, the division behind well-known products like Doliprane, a popular painkiller in France.

French govt set to take stake in Sanofi unit after PE sale

Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

Sanofi enters exclusive talks with CD&R for Opella sale

Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development journey Sanofi to become a focused science-driven biopharma delivering innovative medicines and vaccines to patients Sanofi 2024 business EPS guidance upgraded today Paris, October 21, 2024 . Sanofi and CD&R announce today a plan to join forces to fuel Opella's ambitions as a French-headquartered, global consumer healthcare champion.

Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare

France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.

News for Sanofi Stock (SNY)